NAMSA recently announced that it has launched its new online development application known as the NAMSA Biocompatibility Strategy Navigator.
The web-based resource helps device manufacturers simplify the process of identifying correct biological endpoint assessments for global regulatory submission pathways. The system uses the most up-to-date regulatory requirements to give instant recommendations to global manufacturers for cost-effective streamline development initiatives.
“We are extremely pleased to offer the industry’s first online solution designed to provide medical device organizations with unprecedented, customized access to the biological tests required for regulatory approval,” said Jean-Pierre Boutrand, VP of global laboratory services at NAMSA. “This novel tool is the only resource available in the marketplace with no-cost, open access that delivers strategic recommendations in four simple steps.”
NAMSA offers companies programs that help fast-track development efforts. The organization supports the toxicology, microbiology, chemistry and biocompatibility testing services industries.
“We are confident that this new application will serve as a valuable resource for global manufacturers as we work together to bring life-saving medical technologies to the market in the most efficient manner possible,” Boutrand said.